Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflutren - Molecular Biosystems

Drug Profile

Perflutren - Molecular Biosystems

Alternative Names: FS-069; Octafluoropropane; Optison; Perfluoropropane

Latest Information Update: 10 Aug 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Biosystems
  • Developer Chugai Pharmaceutical; GE Healthcare; Molecular Biosystems; OncoGenex Pharmaceuticals
  • Class Contrast media; Fluorocarbons
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Left ventricular dysfunction

Most Recent Events

  • 25 Jun 2009 CHMP of the EMEA recommends the lifting of the suspension of the marketing authorisation for Perflutren in the European Union
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
  • 22 Apr 2005 Discontinued - Phase-II/III for Left ventricular dysfunction (diagnosis) in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top